Skip to main content

Table 1 Patient demographics and clinical characteristics and probability of VTE and major bleeding

From: Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study

  N (%)VTEPEBleeding
Total 2553208 (8.21)93 (3.6)341 (13.4)
Age<  55398 (15.6)45 (11.3)18 (4.5)42 (10.8)
 55–65724 (28.4)73 (10.1)27 (3.7)83 (11.5)
 65–75703 (27.5)54 (7.7)24 (3.4)103 (14.7)
 ≥ 75728 (28.5)36 (5.0)24 (3.3)112 (15.4)
GenderMale1765 (69.1)141 (8.0)54 (3.1)260 (14.7)
 Female788 (30.9)67 (8.5)39 (4.9)81 (10.3)
Charlson’s comorbidity Index≤ 51811 (70.9)159 (8.8)37 (2.7)239 (13.2)
 >  5742 (29.1)49 (6.6)56 (4.8)102 (13.8)
MetastaticNo1018 (39.9)41 (4.0)16 (1.6)125 (12.3)
 Yes1535 (60.1)167 (10.9)77 (5.0)216 (14.1)
VTE concomitant with cancer diagnosisNo2489 (97.5)201 (8.1)90 (3.6)329 (13.2)
 Yes64 (2.5)7 (10.9)3 (4.7)12 (18.8)
Anticoagulant or antiplatelet treatmentNo1706 (66.8)158 (76.0)71 (76.3)199 (58.4)
Yes847 (33.2)50 (24.0)22 (23.7)142 (41.6)
Anticoagulant therapyNo2338 (91.6)195 (8.3)86 (3.7)293 (12.5)
 Yes215 (8.4)13 (6.1)7 (3.3)48 (22.3)
Antiplatelet therapyNo1851 (72.5)168 (9.1)78 (4.2)227 (12.3)
 Yes702 (27.5)40 (5.7)15 (2.1)114 (16.2)
NSAID therapyNo2255 (88.3)175 (7.8)80 (3.6)311 (13.8)
 Yes298 (11.7)33 (11.1)13 (4.4)30 (10.1)